How to get a compounded GLP-1 prescription in 2026

The short answer: in 2026, most people cannot lawfully get routine compounded semaglutide or tirzepatide, and most people do not need to. The shortages that allowed mass compounding ended in 2024 and 2025. A compounded GLP-1 is still possible when a prescriber documents a specific clinical need that the approved product cannot meet, and branded cash prices have fallen into the range compounded products used to occupy.

This guide covers access only: the rules, how to check a pharmacy, and costs. It does not cover dosing, which belongs with your prescriber and the product label.

Why compounded GLP-1s were everywhere, and why that ended

Pharmacies can make copies of an approved drug while it is on FDA's drug shortage list. Semaglutide and tirzepatide were both listed during the demand surge, and compounded versions were widely sold through pharmacies and telehealth programs. [1]

Then supply caught up:

• Tirzepatide: FDA declared the shortage resolved on October 2, 2024 and reaffirmed that decision on December 19, 2024 after reconsideration. The grace period for 503A pharmacies ended February 18, 2025, and for 503B outsourcing facilities on March 19, 2025. [2]
• Semaglutide: FDA declared the shortage resolved on February 21, 2025. The 503A grace period ended April 22, 2025, and the 503B grace period on May 22, 2025. [2]

The tirzepatide side of this story, including what the end of its shortage means for compounded vials, is in our compounded tirzepatide guide.

Every date is on the semaglutide regulatory timeline.

Outside a shortage, federal law bars a 503A pharmacy from regularly compounding drugs that are essentially copies of a commercially available drug. The exception is a change the prescriber determines makes a significant difference for that patient. [3] In practice that means things like an allergy to an inactive ingredient in the branded pen, or a dose strength the manufacturer does not make. [1]

Step 1: Decide whether you actually need compounded product

Ask your prescriber two questions. Is there a clinical reason the approved product will not work for me? And if cost is the reason, have we checked the branded cash price and my insurance? Cost alone is not a patient-specific clinical need.

Compare the options before you choose. Our semaglutide vs tirzepatide comparison lays out the head-to-head trials and label differences, and the obesity condition page shows how each is graded.

Step 2: Find a licensed prescriber, in person or by telehealth

Any prescriber must be licensed in the state where you are located when you are treated. GLP-1 drugs are not controlled substances, so the federal rule requiring an in-person visit before prescribing controlled substances online does not apply. [6] Each state sets its own rules for how a telehealth relationship is established. Texas, for example, lists the methods that can create a valid practitioner-patient relationship by telemedicine, including synchronous audio-video visits and store-and-forward records. [7] Our Texas guide covers the details, and the state legal guides cover the rest.

A good prescriber will review your history, check contraindications on the label, and tell you in writing why compounded product is needed if they prescribe it. [9] [10]

Step 3: Verify the pharmacy

Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before they are sold. [4] That puts the burden on checking the pharmacy.

• State license. The pharmacy must be licensed by the board of pharmacy in your state, including a nonresident license if it ships from elsewhere. Boards publish license lookups; in Texas, that is the Texas State Board of Pharmacy. [8]
• 503A or 503B. A 503A pharmacy fills patient-specific prescriptions. A 503B outsourcing facility registers with FDA, follows federal manufacturing standards, and is inspected by FDA. [5]
• Active ingredient. FDA has warned about compounded products made with salt forms such as semaglutide sodium and semaglutide acetate, which are not the active ingredient in the approved drugs. Ask what the ingredient is and where it came from. [1]
• No research labels. A product sold as "research use only" is not a compounded prescription and is not lawful for human use.

Step 4: Know what the branded route costs

For many people the numbers now favor the brand. See the full price index for semaglutide and tirzepatide.

• List price: about 1,349 USD a month for Wegovy and about 1,059 USD a month for Zepbound before insurance. [11] [12]
• Manufacturer cash programs: roughly 349 to 499 USD a month for branded Wegovy, and for Zepbound single-dose vials depending on dose. [11] [12]
• Insurance: often 0 to 25 USD a month with a savings card when the plan covers the prescribed indication. Many employer plans exclude weight-management drugs, and Medicare Part D plans may not cover a drug prescribed only for weight loss. [13]
• Compounded (historical): about 200 to 400 USD a month for semaglutide and 250 to 500 USD for tirzepatide during the shortage. Those ranges are from the shortage era, not current primary-source prices.

Step 5: Watch for red flags

Walk away from any program that:

• Offers compounded semaglutide or tirzepatide to anyone who fills out a form, with no discussion of clinical need.
• Will not name the dispensing pharmacy or its license.
• Describes its product as "generic Wegovy" or "the same as Ozempic." Compounded drugs are not approved generics. [4]
• Ships vials labeled for research use.

The bottom line

Compounded GLP-1s did not disappear, but the lawful path narrowed to people with a documented clinical reason. For everyone else, the practical route in 2026 is a licensed prescriber and the branded product, through insurance or a manufacturer cash program.

For approval status, prices, and state access across the whole drug class, see the GLP-1 hub.